Medical Cannabis for PTSD in the UK: What Patients Need to Know

What Is PTSD and Why Is It So Difficult to Treat?

Post-traumatic stress disorder (PTSD) is a serious mental health condition that can develop after exposure to a traumatic event — such as military combat, sexual assault, a serious accident, or the sudden loss of a loved one. In the UK, it is estimated that around 4% of the population will experience PTSD at some point in their lives, with many cases going undiagnosed or undertreated for years.

The condition is characterised by intrusive flashbacks, nightmares, hypervigilance, emotional numbness, and severe anxiety. Conventional treatments — primarily cognitive behavioural therapy (CBT) and antidepressants such as SSRIs — are effective for many patients, but a significant proportion find that these approaches provide only partial relief or are associated with intolerable side effects.

It is precisely this treatment-resistant group that has driven growing interest in cannabis-based medicinal products (CBPMs) as an alternative or adjunct therapy for PTSD.

What Does the Evidence Say?

The UK Medical Cannabis Registry (UKMCR), which tracks real-world clinical outcomes for patients prescribed CBPMs in the UK, has published some of the most compelling evidence to date. A 2025 analysis of registry data found that patients prescribed CBMPs for PTSD reported statistically significant improvements in PTSD symptom severity, anxiety, sleep quality, and overall health-related quality of life at follow-up intervals of up to 18 months.

Specifically, the registry data showed reductions in scores on validated PTSD assessment tools, alongside improvements in sleep disturbance — one of the most debilitating and treatment-resistant aspects of the condition. Patients also reported reductions in anxiety and depression scores, which commonly co-occur with PTSD.

These findings are consistent with earlier research. A 2024 study published in BJPsych Open examined real-world evidence from UK patients prescribed cannabis for PTSD and comorbid depression, finding substantial reductions in PTSD symptomatology. The researchers noted that cannabis appeared to act on the endocannabinoid system in ways that may help regulate the fear response and emotional memory processing — two core mechanisms disrupted in PTSD.

How Does Cannabis Work for PTSD?

The endocannabinoid system plays a central role in regulating fear, stress, and emotional memory. Cannabinoid receptors (CB1 and CB2) are found in high concentrations in the amygdala, hippocampus, and prefrontal cortex — precisely the brain regions most implicated in PTSD.

THC (tetrahydrocannabinol) is thought to help suppress intrusive memories and reduce the emotional intensity of traumatic recollections by acting on CB1 receptors in the amygdala. CBD (cannabidiol), meanwhile, has anxiolytic and neuroprotective properties that may help reduce hyperarousal and improve sleep architecture. Many patients prescribed CBMPs for PTSD receive balanced THC:CBD formulations, though the optimal ratio varies by individual.

Can You Get a Medical Cannabis Prescription for PTSD in the UK?

Yes. PTSD is a recognised condition for which specialist doctors in the UK can prescribe cannabis-based medicinal products. However, it is important to understand that NHS prescriptions for PTSD remain extremely rare. In practice, the vast majority of PTSD patients accessing CBMPs in the UK do so through private specialist clinics.

To be eligible, patients typically need to demonstrate that they have a confirmed PTSD diagnosis and have tried at least two conventional treatments (such as CBT and an SSRI) without achieving adequate symptom control. A specialist doctor will review your full medical history before making any prescribing decision.

CPGUK can help connect you with specialist clinics and guide you through the process of accessing a private prescription. Our service is free, confidential, and carries no obligation.

What Should PTSD Patients Expect?

If you are prescribed a CBMP for PTSD, your doctor will typically start you on a low dose and titrate upward gradually, monitoring your response at regular review appointments. Most patients use cannabis oil (taken sublingually) or dried flower (vaporised using a medical-grade vaporiser) — smoking is not a recommended route of administration.

It is important to keep your GP informed of any new prescriptions, including CBMPs, so that your overall care can be coordinated safely. You should also be aware that driving after using THC-containing products requires careful judgement — if you feel any cognitive impairment, you should not drive.

Getting Support from CPGUK

CPGUK is a non-profit patient advocacy organisation dedicated to helping UK patients access medical cannabis legally and safely. If you are living with PTSD and have not found adequate relief through conventional treatments, we encourage you to get in touch. Our team can explain the process, answer your questions, and help you take the first step towards a specialist consultation.